TP53 and acute myeloid leukemia: Given TP53-mutated AML’s altered immune profile, spanning both innate and adaptive immunity, a trial of atezolizumab, an anti-PD-L1 antibody, and magrolimab will assess activity in relapsed or refractory AML patients (NCT03922477).